Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2024 08:00 ET | Source: OncoC4, Inc.

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO

Dr. Wakelee is a world-renowned expert in the research and treatment of lung cancerOncoC4’s SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and...
February 22, 2024 08:00 ET | Source: OncoC4, Inc.

OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program

The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with metastatic...
January 04, 2024 08:00 ET | Source: OncoC4, Inc.

OncoC4 to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced its participation in the 42nd...
September 28, 2023 08:00 ET | Source: OncoC4, Inc.

OncoC4 Strengthens Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief...
December 30, 2022 10:43 ET | Source: OncoC4, Inc.

UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

ROCKVILLE, Md., Dec. 30, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed...
December 30, 2022 08:27 ET | Source: OncoC4, Inc.

OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial ONC-392 is the first known acid...
November 07, 2022 08:00 ET | Source: OncoC4, Inc.

OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022

30% ORR and 90% DCR in evaluable patients were achieved in the dose escalation portion of the study in metastatic cancer patientsInitial results from dose-expansion show 5 partial responses (PR) and 1...
April 26, 2022 08:00 ET | Source: OncoC4, Inc.

OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC

ROCKVILLE, Md., April 26, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical stage biopharma company developing novel immunotherapies for cancer, announced today that the U.S. Food and Drug...
November 09, 2021 08:00 ET | Source: OncoC4, Inc.

OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors

Data Suggest that ONC-392 Monotherapy has Promising Anti-tumor Activity in Stage IV Cancer Patients Who Have Failed Multiple Lines of Prior Therapy Company Plans to advance into Phase II/III studies ...